Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AML
Covered in this story
Call it yourself
No calls on $ASH yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ashland →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.